Dust mite allergy double-blind placebo controlled

Bousquet J, Scheinmann P, Guinnepain MT, Perrin-Fayolle M, Sauvaget J, Tonnel AB, Pauli G, Caillaud D, Dubost R, Leynadier F, Vervloet D, Herman D, Galvain S, Andre C Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites A double blind placebo-controlled study. Allergy 1999 54/3 249-260. 

Guez S, Vatrinet C, Fadel R, Andre C House dust mite SLIT in perennial rhinitis A double blind placebo controlled study. Allergy 2000 55 369-375. 

Hirsch T, Sahn M, Leupold W Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol 1997 8 21-27. Bahceciler NN, Isik U, Barlan IB, Basaran MM Efficacy of sublingual immunotherapy in children with asthma and rhinitis A double-blind, placebo-controlled study. Pediatr Pulmonol... 

Hirsch TH, Sahn M, Leupold W Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol 1997 8 21-27. 

La Rosa M, Ranno C, Andre C, Carat F, Tosca MA, Canonica GW Double-blind placebo-controlled evaluation of sublingual swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999 104 425 432. Guez S, Vatrinet C, Fadel R, Andre C House dust mite sublingual swallow immunotherapy in perennial rhinitis A double-blind placebo-controlled study. Allergy 2000 55 369-375. 

The efficacy of subcutaneous SIT has been clearly shown in a metaanalysis of 43 double-blind placebo-controlled trials in allergic rhinitis as well as another meta-analysis of 16 double-blind placebo-controlled studies in asthma patients [13]. The mean clinical improvement was 45% reduction in symptoms and medication compared with placebo in rhinitis and 40% in asthma patients, which exceeds the effects of drug therapy. A recent meta-analysis also confirmed that asthma responds favorably to SIT [14], However, recently it could also be demonstrated that SIT is effective in patients with house dust mite allergy, allergic rhinitis and asthma [15]. Immunotherapy in these patients not only reduced rhinitis and asthma symptoms as well as rescue medication, but also had an impact on bronchial hyperreactivity over the 3-year follow-up period. 

Olsen O, Larsen K, Jacobsan L, Svendsen U A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 1997 52 853-859. 

---